Quest Diagnostics (DGX) Osake Kurssi
Quest Diagnostics Kurssi
Viimeisten 19 vuoden aikana Quest Diagnosticsn liikevaihto kasvoi 3,0 % vuodessa ja ylsi 11,04 Mrd. USD:een. Osakekohtainen tulos on kasvanut 5,8 % vuodessa viimeisten 19 vuoden aikana. Quest Diagnosticsn nettomarginaali 9,0 % on laskenut verrattuna 18,5 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,34 %. Jakosuhde on noin 36 % tuloksesta. Osinko on kasvanut 11,6 % vuodessa viimeisten 19 vuoden aikana. Quest Diagnosticsn 12 kuukauden konsensustavoitehinta on 247,50 USD, noin yli kurssia 4,9 %. 23 analyytikosta 13 suosittaa ostoa — kokonaiskonsensus on Osta.
Quest Diagnostics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Quest Diagnostics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Quest Diagnostics -osakkeesta
Quest Diagnostics Inc. operates as a provider of diagnostic testing and information services. It offers a range of services including routine testing, complex and specialized testing, and diagnostic information services. The company operates a network of laboratories, patient service centers, and other testing sites across the United States. Quest Diagnostics Inc. collaborates with physicians, hospitals, and other healthcare organizations to help improve patient care. Its business model revolves around delivering accurate and reliable diagnostic testing results in a timely manner, assisting healthcare providers in making informed decisions, and ultimately improving patient outcomes.
Quest Diagnostics Inc is primarily active in the healthcare industry.
The main competitors of Quest Diagnostics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Sonic Healthcare Limited, and Bio-Reference Laboratories.
Quest Diagnostics Inc is a leading provider of diagnostic information services. It was founded in 1967 as MetPath and became Quest Diagnostics in 1997. The company offers a wide range of services, including lab testing, clinical trials, and healthcare IT solutions. With a strong focus on innovation and quality, Quest Diagnostics has become a trusted name in the healthcare industry. It operates a vast network of laboratories across the United States, serving millions of patients and healthcare professionals. Quest Diagnostics is known for its commitment to accuracy, efficiency, and delivering timely results, making it a reliable partner for both patients and healthcare providers.
Quest Diagnostics Inc has achieved several significant milestones throughout its history. One of its noteworthy achievements includes the development of innovative diagnostic tests and services that have revolutionized the healthcare industry. Additionally, Quest Diagnostics Inc has successfully established a vast network of laboratories and patient service centers, ensuring convenient access to high-quality diagnostic information services for patients worldwide. Furthermore, the company has received numerous accolades for its commitment to quality, including ISO 9001 certification for its laboratory operations. These accomplishments highlight Quest Diagnostics Inc as a leading provider of diagnostic information services and showcase its dedication to improving patient care and outcomes.
Quest Diagnostics Inc is primarily present in the United States.
Quest Diagnostics Inc represents values of empowerment, collaboration, and integrity. As a leading provider of diagnostic testing and information services, the company is committed to delivering high-quality healthcare solutions. Quest Diagnostics believes in patient-centric care and strives to improve both individual and public health outcomes. With a corporate philosophy focused on innovation and excellence, Quest Diagnostics prioritizes accuracy, efficiency, and accessibility in their diagnostic services. Through extensive research and development, the company continually advances medical technologies to contribute to the progress of the healthcare industry.
Analyytikot asettavat tällä hetkellä Quest Diagnostics-osakkeelle keskimääräisen tavoitehinnan 244,50 USD (mediaani: 247,50 USD), mikä merkitsee +3,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 23 analyytikkoarvioon.
23 analyytikkoa arvioi tällä hetkellä Quest Diagnostics-osaketta: 13 suosittaa ostoa, 10 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Quest Diagnostics-yhtiöltä 12,01 Mrd. USD liikevaihtoa ja 11,30 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Quest Diagnostics-osake noteerataan hintaan 209,87 EUR (235,93 USD).
Quest Diagnostics-osake (DGX) on listattuna 8 pörssissä, muun muassa: NYSE (DGX), London (0KSX.L), SIX (Zürich) (QDI.SW), XETRA (QDI.DE), Frankfurt (QDI.F), München (QDI.MU), Düsseldorf (QDI.DU).
Quest Diagnostics Inc is a leading provider of diagnostic laboratory tests and services worldwide. The company serves medical laboratories, hospitals, clinics, physicians, as well as companies and insurers globally. The company's business strategy is based on providing high-quality laboratory facilities, state-of-the-art technology, and a high-quality laboratory workflow management platform. It operates over 2,200 patient centers in the United States and also offers a mobile laboratory service. The company is divided into three main segments: 1. Diagnostic information services, 2. Diagnostic services, and 3. Diagnostic solutions. Quest Diagnostics offers a wide range of products and services used to diagnose and treat diseases and conditions, including blood tests, hormone analyses, microbiology tests, genetic tests, immunology tests, and more. The company also operates a pathology laboratory that provides specialized services for cancer diagnosis and other critical diseases. It has also specialized in the development of tests for detecting COVID-19. Overall, Quest Diagnostics has a strong business model based on its leading position in the diagnostic market, a wide range of products and services, and a strong presence in the United States and growing international presence. The company is also focused on expanding its capabilities in digital health technology to meet the changing healthcare landscape.
odotettu liikevaihto Quest Diagnostics on 12,01 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Quest Diagnostics on 1,27 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Quest Diagnostics:n hinta-voitto-suhde (P/E) on tällä hetkellä 20,89. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Quest Diagnostics-osakkeen arvostusta.
Quest Diagnostics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,20. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Quest Diagnostics-osakkeen arvostuskennuslukuna.
Quest Diagnostics:n Eulpool-laatuscore on 2/10.
Quest Diagnostics:n ISIN on US74834L1008. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Quest Diagnostics:n WKN on 904533. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Quest Diagnostics:n ticker on DGX. Tämä pörssinoteeraus käytetään Quest Diagnostics-osakkeiden kauppaan pörssissä.
Quest Diagnostics osake
Quest Diagnostics vertaisryhmä
Quest Diagnostics Ticker
Quest Diagnostics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Quest Diagnostics:sta
Meidän osakeanalyysimme Quest Diagnostics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Quest Diagnostics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: